These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11715183)

  • 1. The dilemma of late-stage heart failure. Rationale for chronic parenteral inotropic support.
    Mehra MR; Uber PA
    Cardiol Clin; 2001 Nov; 19(4):627-36. PubMed ID: 11715183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotropic therapy for heart failure: an evidence-based approach.
    Felker GM; O'Connor CM
    Am Heart J; 2001 Sep; 142(3):393-401. PubMed ID: 11526351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral inotropic support for advanced congestive heart failure.
    Leier CV; Binkley PF
    Prog Cardiovasc Dis; 1998; 41(3):207-24. PubMed ID: 9872607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
    Shakar SF; Abraham WT; Gilbert EM; Robertson AD; Lowes BD; Zisman LS; Ferguson DA; Bristow MR
    J Am Coll Cardiol; 1998 May; 31(6):1336-40. PubMed ID: 9581729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient parenteral inotropic therapy for advanced heart failure.
    Young JB; Moen EK
    J Heart Lung Transplant; 2000 Aug; 19(8 Suppl):S49-57. PubMed ID: 11016488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology.
    Gustafsson F; Damman K; Nalbantgil S; Van Laake LW; Tops LF; Thum T; Adamopoulos S; Bonios M; Coats AJ; Crespo-Leiro MG; Mehra MR; Filippatos G; Hill L; Metra M; Jankowska E; de Jonge N; Kaye D; Masetti M; Parissis J; Milicic D; Seferovic P; Rosano G; Ben Gal T
    Eur J Heart Fail; 2023 Apr; 25(4):457-468. PubMed ID: 36847113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of novel inotropic agents in the treatment of heart failure.
    LeJemtel TH; Keren G; Reis D; Sonnenblick EH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 9():S47-54. PubMed ID: 2433542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term intravenous inotropes in low-output terminal heart failure?
    von Scheidt W; Pauschinger M; Ertl G
    Clin Res Cardiol; 2016 Jun; 105(6):471-81. PubMed ID: 26879807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational use of inotropic therapy in heart failure.
    Felker GM; O'Connor CM
    Curr Cardiol Rep; 2001 Mar; 3(2):108-13. PubMed ID: 11177666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
    Metra M; Nodari S; D'Aloia A; Muneretto C; Robertson AD; Bristow MR; Dei Cas L
    J Am Coll Cardiol; 2002 Oct; 40(7):1248-58. PubMed ID: 12383572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inotropic agents].
    Yasumura Y
    Nihon Rinsho; 2006 May; 64(5):927-33. PubMed ID: 16689376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "I Just Feel Like I Always Did": Inotropic Dependency at End of Life.
    Latimer A; Pope ND; McFarlin JM
    Am J Hosp Palliat Care; 2020 Jul; 37(7):497-502. PubMed ID: 31714150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inotropic therapy in heart failure: general aspects and clinical results].
    Manito N; Kaplinsky EJ; Pujol R
    Med Clin (Barc); 2004 Feb; 122(7):269-74. PubMed ID: 15012878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-digitalis inotropic agents in the treatment of congestive heart insufficiency].
    Correia JF
    Rev Port Cardiol; 1989 Jun; 8(6):473-81. PubMed ID: 2698714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering?
    Uretsky BF
    Postgrad Med J; 1986 Jun; 62(728):585-92. PubMed ID: 2946034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT; Janicki JS; Jain MC
    J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of nonglycosidic inotropic agents: indications, ethics, and limitations.
    Chatterjee K; De Marco T
    Med Clin North Am; 2003 Mar; 87(2):391-418. PubMed ID: 12693731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan: a new therapeutic option in the treatment of primary graft dysfunction after heart transplantation.
    Weis F; Beiras-Fernandez A; Kaczmarek I; Sodian R; Kur F; Weis M; Schmoeckel M; Reichart B
    J Heart Lung Transplant; 2009 May; 28(5):501-4. PubMed ID: 19416780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy.
    Stevenson LW
    Circulation; 2003 Jul; 108(4):492-7. PubMed ID: 12885733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.